Compositions and methods for enhancing drug delivery across and into ocular tissues
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/03
A61K-038/16
출원번호
US-0608975
(2012-09-10)
등록번호
US-8729010
(2014-05-20)
발명자
/ 주소
Rothbard, Jonathan B.
Wender, Paul A.
McGrane, Leo P.
Sista, Lalitha V. S.
Kirschberg, Thorsten A.
출원인 / 주소
KAI Pharmaceuticals, Inc.
대리인 / 주소
McDermott Will & Emery LLP
인용정보
피인용 횟수 :
0인용 특허 :
33
초록▼
This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including into and across ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier.
This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including into and across ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.
대표청구항▼
1. A method for enhancing delivery of a compound into and across an animal ocular tissue, the method comprising: administering to the ocular tissue a conjugate comprising the compound and a delivery-enhancing transporter, wherein:i. the compound is attached to the delivery-enhancing transporter thro
1. A method for enhancing delivery of a compound into and across an animal ocular tissue, the method comprising: administering to the ocular tissue a conjugate comprising the compound and a delivery-enhancing transporter, wherein:i. the compound is attached to the delivery-enhancing transporter through a disulfide linker, andii. the delivery-enhancing transporter comprises fewer than 50 subunits and comprises at least 5 guanidine or amidino moieties, thereby increasing delivery of the conjugate into the ocular tissue compared to delivery of the compound in the absence of the delivery-enhancing transporter. 2. The method of claim 1, wherein delivery of the conjugate into the ocular tissue is increased at least two-fold compared to delivery of the compound in the absence of the delivery-enhancing transporter. 3. The method of claim 1, wherein delivery of the conjugate into the ocular tissue is increased at least ten-fold compared to delivery of the compound in the absence of the deliver-enhancing transporter. 4. The method of claim 1, wherein the ocular tissue is one or more layers of epithelial or endothelial tissue. 5. The method of claim 1, wherein the ocular tissue is the retina. 6. The method of claim 1, wherein the ocular tissue is the optic nerve. 7. The method of claim 1, wherein the subunits are amino acids. 8. The method of claim 1, wherein the conjugate comprises at least two delivery-enhancing transporters. 9. The method of claim 1, wherein the conjugate is administered as an eye drop. 10. The method of claim 1, wherein the delivery-enhancing transporter consists essentially of 5 to 50 amino acids, at least 50 percent of which amino acids are arginines or analogs thereof. 11. A method for enhancing delivery of a compound into and across an animal ocular tissue, the method comprising: administering to the ocular tissue a conjugate comprising the compound and a delivery-enhancing transporter, wherein:i. the compound is attached to the delivery-enhancing transporter through a photocleavable linker, andii. the delivery-enhancing transporter comprises fewer than 50 subunits and comprises at least 5 guanidine or amidino moieties, thereby increasing delivery of the conjugate into the ocular tissue compared to delivery of the compound in the absence of the delivery-enhancing transporter. 12. The method of claim 11, wherein delivery of the conjugate into the ocular tissue is increased at least two-fold compared to delivery of the compound in the absence of the delivery-enhancing transporter. 13. The method of claim 11, wherein delivery of the conjugate into the ocular tissue is increased at least ten-fold compared to delivery of the compound in the absence of the delivery-enhancing transporter. 14. The method of claim 11, wherein the ocular tissue is one or more layers of epithelial or endothelial tissue. 15. The method of claim 11, wherein the ocular tissue is the retina. 16. The method of claim 11, wherein the ocular tissue is the optic nerve. 17. The method of claim 11, wherein the subunits are amino acids. 18. The method of claim 11, wherein the conjugate comprises at least two delivery-enhancing transporters. 19. The method of claim 11, wherein the conjugate is administered as an eye drop. 20. The method of claim 11, wherein the delivery-enhancing transporter consists essentially of 5 to 50 amino acids, at least 50 percent of which amino acids are arginines or analogs thereof.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (33)
Nichols Alfred C. (Texas City TX) Yielding K. Lemone (Galveston TX), 4-hydroxyquinaldic acid derivatives.
Shen Wei C. (145 Richdale Rd. Needham MA 02194) Ryser Hugues J. (503 Annursnac Hill Rd. Concord MA 01742), Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers.
Rothbard, Jonathan B.; Wender, Paul A.; McGrane, P. Leo; Sista, Lalitha V. S.; Kirschberg, Thorsten A., Compositions and methods for enhancing drug delivery across and into epithelial tissues.
Rothbard, Jonathan B.; Wender, Paul A.; McGrane, P. Leo; Sista, Lalitha V. S.; Kirschberg, Thorsten A., Compositions and methods for enhancing drug delivery across and into epithelial tissues.
Rothbard, Jonathan B.; Wender, Paul A.; McGrane, P. Leo; Sista, Lalitha V. S.; Kirschberg, Thorsten A., Compositions and methods for enhancing drug delivery across and into epithelial tissues.
Rothbard, Jonathan B.; Wender, Paul A.; McGrane, P. Leo; Sista, Lalitha V. S.; Kirschberg, Thorsten A., Compositions and methods for enhancing drug delivery across and into ocular tissues.
Rothbard,Jonathan B.; Wender,Paul A.; McGrane,P. Leo; Sista,Lalitha V. S.; Kirschberg,Thorsten A., Compositions and methods for enhancing drug delivery across and into ocular tissues.
Rothbard, Jonathan B.; Wender, Paul A.; McGrane, P. Leo; Sista, Lalitha V. S.; Kirschberg, Thorsten A., Compositions and methods for treating inflammatory diseases of the skin.
Kozarich John W. (Cambridge MA) Musso Gary F. (Hopkinton MA) Malfroy-Camine Bernard (Arlington MA), Increasing blood-brain barrier permeability with permeabilizer peptides.
Katz Robert ; Tomoaia-Cotisel Maria, Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-.
Skubitz Amy P. N. ; Furcht Leo T. ; Balles Mark ; Gregerson Dale S. ; Agarwal Anita ; Wright Martha M. ; Murali Shobana, Method for treating conditions of the eye using polypeptides.
Sumner-Smith Martin (Bolton CAX) Barnett Richard W. (Mississauga CAX) Reid Lorne S. (Toronto CAX) Sonenberg Nahum (St. Luc CAX), Peptide-based inhibitors of HIV replication.
Brewer Stephen J. (High Wycombe GB2) Sassenfeld Helmut M. (Benson GB2), Process for the preparation of polypeptides utilizing a charged amino acid polymer and exopeptidase.
Dean Richard T. (Downingtown PA) Boutin Raymond H. (Wilmington DE) Lister-James John (Glenmoore PA), Proteins modified with positively charged carriers and compositions prepared therefrom.
Twist ; deceased Michael (late of Toronto CAX by Harvey L. Hamburg ; Administrator ) Sumner-Smith Martin (Bolton CAX), Treatment of cytomegalovirus infection.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.